Business
Oxford BioMedica Appoints Corporate Broker
Oxford BioMedica Appoints Corporate Broker.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 4026Y Oxford Biomedica PLC 17 May 2016 \n\nOxford BioMedica Appoints Corporate Broker \n \n \nOxford, UK - 17 May 2016: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Group\") (LSE:OXB), a leading gene and cell therapy group, is pleased to announce that it has appointed Jefferies Hoare Govett as Sole Corporate Broker with immediate effect.\n \n-Ends-\n \n\n\n\n\nFor further information, please contact:\n\n\n \n\n\n\n\n \nOxford BioMedica plc:\nJohn Dawson, Chief Executive Officer\nTim Watts, Chief Financial Officer\n\n\n \nTel: +44 (0)1865 783 000\n\n\n\n\n \nFinancial and corporate communications enquiries:\nConsilium Strategic Communications\nMary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton\n\n\n \nTel: +44 (0)20 3709 5700\n\n\n\n\n \nJefferies Hoare Govett:\nSimon Hardy\nMax Jones\nChris Binks\n\n\n \nTel: +44 (0)20 7029 8000\n\n\n\n\n \nNotes for editors\n \nAbout Oxford BioMedica®\nOxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the \"Group\") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.\n \n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END MSCAKADBCBKDNPD\n ","length":3546,"tagName":"div"}]